Protagonist Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 21, 2025
PTGX$135.90+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, | ||||||
| | 2024 | 2023 | ||||
| Assets | | | | | | |
| Current assets: | | | | | | |
| Cash and cash equivalents | | $97,249 | | $186,727 | ||
| Marketable securities | | | 321,664 | | | 154,890 |
| Receivable from collaboration partner | | | 165,000 | | | 10,000 |
| Prepaid expenses and other current assets | | | 7,728 | | | 3,960 |
| Total current assets | | | 591,641 | | | 355,577 |
| Marketable securities - noncurrent | | | 140,252 | | | — |
| Property and equipment, net | | | 3,190 | | | 1,195 |
| Restricted cash - noncurrent | | | 225 | | | 225 |
| Operating lease right-of-use asset | | | 9,417 | | | 954 |
| Total assets | | $744,725 | | $357,951 | ||
| Liabilities and Stockholders’ Equity | | | | | | |
| Current liabilities: | | | | | | |
| Accounts payable | | $1,615 | | $772 | ||
| Payable to collaboration partner | | | — | | | 3 |
| Accrued expenses and other payables | | | 23,693 | | | 19,358 |
| Deferred revenue | | | 18,891 | | | — |
| Income taxes payable | | | 2,689 | | | — |
| Operating lease liability | | | 510 | | | 1,141 |
| Total current liabilities | | | 47,398 | | | 21,274 |
| Deferred revenue - noncurrent | | | 11,676 | | | — |
| Operating lease liability - noncurrent | | | 10,356 | | | — |
| Total liabilities | | | 69,430 | | | 21,274 |
| Commitments and contingencies (Note 9) | | | | | | |
| Stockholders’ equity: | | | | | | |
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding | | | — | | | — |
| Common stock, $0.00001 par value, 180,000,000 and 90,000,000 shares authorized as of December 31, 2024 and 2023, respectively; 61,035,139 and 57,708,613 shares issued and outstanding as of December 31, 2024 and 2023, respectively | | | 1 | | | 1 |
| Additional paid-in capital | | | 1,015,898 | | | 952,491 |
| Accumulated other comprehensive loss | | | (82) | | | (105) |
| Accumulated deficit | | | (340,522) | | | (615,710) |
| Total stockholders’ equity | | | 675,295 | | | 336,677 |
| Total liabilities and stockholders’ equity | | $744,725 | | $357,951 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.